{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:23:42Z","timestamp":1793910222674,"version":"4.8.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005347","name":"American Association for the Study of Liver Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Treatment choices in hepatocellular carcinoma (HCC) involve consideration of tradeoffs between the benefits, toxicities, inconvenience, and costs. Stated preference elicitation methods have been used in the medical field to help evaluate complex treatment decision-making. The aim of this study was to conduct a scoping review to assess the evidence base for the use of preference elicitation tools or willingness to pay\/willingness to accept methods for HCC treatment decision-making from both the patient and provider perspective.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a scoping review to identify abstracts or manuscripts focused on the role preference elicitation tools or willingness to pay\/willingness to accept methods for HCC treatment options among patients, caregivers, and\/or providers. Two researchers independently screened full-text references and resolved conflicts through discussion. We summarized key findings, including the type and setting of preference-elicitation tools used for HCC treatment decisions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Ten published abstracts or manuscripts evaluated the role of preference elicitation tools for HCC treatments. The studies revealed several attributes that are considered by patients and providers making HCC treatment decisions. Many of the studies reviewed suggested that while patients place the most value on extending their overall survival, they are willing to forgo overall survival to avoid risks of treatments and maintain quality of life. Studies of physicians and surgeons found that provider preferences are dependent on patient characteristics, provider specialty, and surgeon or hospital-related factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This scoping review explored both patient and physician preferences towards treatment modalities in all stages of HCC. The studies revealed a large scope of potential attributes that may be important to patients and that many patients are willing to forgo survival to maintain quality of life. Further research should explore both preference elicitation of currently available and emerging therapies for HCC as well as the use of this data to develop patient-facing tools to assist in navigating treatment options.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-024-03167-1","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T12:02:53Z","timestamp":1709121773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Scoping review of values elicitation tools for treatment decisions in hepatocellular carcinoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Gabrielle","family":"Ritaccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Sidney","family":"Barritt IV","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie L.","family":"Conklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Evon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna K.","family":"Sanoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Basch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie B.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"issue":"12","key":"3167_CR1","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1016\/j.cgh.2019.07.060","volume":"18","author":"AM Moon","year":"2020","unstructured":"Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol. 2020;18(12):2650\u201366. https:\/\/doi.org\/10.1016\/j.cgh.2019.07.060","journal-title":"Clin Gastroenterol Hepatol Nov"},{"key":"3167_CR2","doi-asserted-by":"publisher","unstructured":"Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatol. 2023;22. https:\/\/doi.org\/10.1097\/HEP.0000000000000466","DOI":"10.1097\/HEP.0000000000000466"},{"key":"3167_CR3","doi-asserted-by":"publisher","first-page":"OP2100227","DOI":"10.1200\/OP.21.00227","volume":"13","author":"G Brar","year":"2021","unstructured":"Brar G, Kesselman A, Malhotra A, Shah MA. Redefining intermediate-stage HCC treatment in the era of immune therapies. JCO Oncol Pract. 2021;13:OP2100227. https:\/\/doi.org\/10.1200\/OP.21.00227","journal-title":"JCO Oncol Pract Jul"},{"key":"3167_CR4","doi-asserted-by":"publisher","unstructured":"Kudo M, Ueshima K, Chan S, et al. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and child-pugh A liver function: a proof-of-concept study. Cancers (Basel). 2019;31(8). https:\/\/doi.org\/10.3390\/cancers11081084","DOI":"10.3390\/cancers11081084"},{"issue":"20","key":"3167_CR5","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"14","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;14(20):1894\u2013905. https:\/\/doi.org\/10.1056\/NEJMoa1915745","journal-title":"N Engl J Med"},{"issue":"10064","key":"3167_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"7","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;7(10064):56\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(16)32453-9","journal-title":"Lancet Jan"},{"issue":"1","key":"3167_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"5","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;5(1):54\u201363. https:\/\/doi.org\/10.1056\/NEJMoa1717002","journal-title":"N Engl J Med"},{"issue":"2","key":"3167_CR8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after Sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282\u201396. https:\/\/doi.org\/10.1016\/S1470-2045(18)30937-9","journal-title":"Lancet Oncol Feb"},{"issue":"10088","key":"3167_CR9","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"24","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;24(10088):2492\u2013502. https:\/\/doi.org\/10.1016\/S0140-6736(17)31046-2","journal-title":"Lancet Jun"},{"issue":"11","key":"3167_CR10","doi-asserted-by":"publisher","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","volume":"1","author":"T Yau","year":"2020","unstructured":"Yau T, Kang YK, Kim TY, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 2020;1(11):e204564. https:\/\/doi.org\/10.1001\/jamaoncol.2020.4564","journal-title":"JAMA Oncol Nov"},{"issue":"7","key":"3167_CR11","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940\u201352. https:\/\/doi.org\/10.1016\/S1470-2045(18)30351-6","journal-title":"Lancet Oncol Jul"},{"issue":"3","key":"3167_CR12","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jhep.2016.10.029","volume":"66","author":"AG Duffy","year":"2017","unstructured":"Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66(3):545\u201351. https:\/\/doi.org\/10.1016\/j.jhep.2016.10.029","journal-title":"J Hepatol Mar"},{"issue":"11","key":"3167_CR13","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/jnci\/djab079","volume":"2","author":"YT Lee","year":"2021","unstructured":"Lee YT, Wang JJ, Luu M, et al. The mortality and overall survival trends of primary liver cancer in the United States. J Natl Cancer Inst. 2021;2(11):1531\u201341. https:\/\/doi.org\/10.1093\/jnci\/djab079","journal-title":"J Natl Cancer Inst Nov"},{"issue":"1","key":"3167_CR14","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1186\/s12885-021-08904-3","volume":"29","author":"J Ding","year":"2021","unstructured":"Ding J, Wen Z. Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database. BMC Cancer. 2021;29(1):1157. https:\/\/doi.org\/10.1186\/s12885-021-08904-3","journal-title":"BMC Cancer Oct"},{"issue":"3","key":"3167_CR15","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/liv.14735","volume":"41","author":"F Garuti","year":"2021","unstructured":"Garuti F, Neri A, Avanzato F, et al. The changing scenario of hepatocellular carcinoma in Italy: an update. Liver Int. 2021;41(3):585\u201397. https:\/\/doi.org\/10.1111\/liv.14735","journal-title":"Liver Int Mar"},{"issue":"6","key":"3167_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/cld.1068","volume":"17","author":"R Salgia","year":"2021","unstructured":"Salgia R, Mendiratta V. The multidisciplinary management of hepatocellular carcinoma. Clin Liver Dis (Hoboken). 2021;17(6):405\u20138. https:\/\/doi.org\/10.1002\/cld.1068","journal-title":"Clin Liver Dis (Hoboken) Jun"},{"issue":"6","key":"3167_CR17","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s40271-021-00520-4","volume":"5","author":"H Collacott","year":"2021","unstructured":"Collacott H, Soekhai V, Thomas C, et al. A systematic review of discrete choice experiments in oncology treatments. Patient. 2021;5(6):775\u201390. https:\/\/doi.org\/10.1007\/s40271-021-00520-4","journal-title":"Patient May"},{"issue":"7","key":"3167_CR18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"2","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;2(7):467\u201373. https:\/\/doi.org\/10.7326\/M18-0850","journal-title":"Ann Intern Med Oct"},{"issue":"1","key":"3167_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jss.2014.02.015","volume":"1","author":"M Molinari","year":"2014","unstructured":"Molinari M, De Coutere S, Krahn M, Helton S, Urbach DR. Patients\u2019 preferences and trade-offs for the treatment of early stage hepatocellular carcinoma. J Surg Res. 2014;1(1):57\u201367. https:\/\/doi.org\/10.1016\/j.jss.2014.02.015","journal-title":"J Surg Res Jun"},{"key":"3167_CR20","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2147\/PPA.S198363","volume":"13","author":"T Chiba","year":"2019","unstructured":"Chiba T, Hiraoka A, Mikami S, et al. Japanese patient preferences regarding intermediate to advanced hepatocellular carcinoma treatments. Patient Prefer Adherence. 2019;13:637\u201347. https:\/\/doi.org\/10.2147\/PPA.S198363","journal-title":"Patient Prefer Adherence"},{"key":"3167_CR21","doi-asserted-by":"publisher","unstructured":"Li D, Tan R, Hernandez S, Reilly N, Bussberg C, Mansfield C. Patient preferences for unresectable hepatocellular carcinoma treatments: a discrete-choice experiment. Cancers (Basel). 2023;25(5). https:\/\/doi.org\/10.3390\/cancers15051470","DOI":"10.3390\/cancers15051470"},{"issue":"1","key":"3167_CR22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12885-022-10388-8","volume":"19","author":"ND Parikh","year":"2023","unstructured":"Parikh ND, Girvan A, Coulter J, et al. Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study. BMC Cancer. 2023;19(1):66. https:\/\/doi.org\/10.1186\/s12885-022-10388-8","journal-title":"BMC Cancer Jan"},{"key":"3167_CR23","doi-asserted-by":"publisher","unstructured":"Lo SH, Sharma R, Costentin CE, et al. Patient preferences for advanced hepatocellular carcinoma treatment: a multicountry stated preference study. Future Oncol. 2021;27. https:\/\/doi.org\/10.2217\/fon-2021-0697","DOI":"10.2217\/fon-2021-0697"},{"issue":"6","key":"3167_CR24","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.2010.30.8650","volume":"20","author":"H Nathan","year":"2011","unstructured":"Nathan H, Bridges JF, Schulick RD, et al. Understanding surgical decision making in early hepatocellular carcinoma. J Clin Oncol. 2011;20(6):619\u201325. https:\/\/doi.org\/10.1200\/JCO.2010.30.8650","journal-title":"J Clin Oncol Feb"},{"issue":"2","key":"3167_CR25","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1245\/s10434-012-2619-5","volume":"20","author":"H Nathan","year":"2013","unstructured":"Nathan H, Segev DL, Bridges JF, et al. Influence of nonclinical factors on choice of therapy for early hepatocellular carcinoma. Ann Surg Oncol. 2013;20(2):448\u201356. https:\/\/doi.org\/10.1245\/s10434-012-2619-5","journal-title":"Ann Surg Oncol Feb"},{"issue":"6","key":"3167_CR26","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1245\/s10434-014-3536-6","volume":"21","author":"H Nathan","year":"2014","unstructured":"Nathan H, Herlong HF, Gurakar A, et al. Clinical decision-making by gastroenterologists and hepatologists for patients with early hepatocellular carcinoma. Ann Surg Oncol. 2014;21(6):1844\u201351. https:\/\/doi.org\/10.1245\/s10434-014-3536-6","journal-title":"Ann Surg Oncol Jun"},{"key":"3167_CR27","doi-asserted-by":"crossref","unstructured":"Chen CM, Hsu CY, Bai CH. Building a patient oriented treatment decision system for liver cancer. Presented at: 2012 Third Global Congress on Intelligent Systems; 2012; Wuhan, China.","DOI":"10.1109\/GCIS.2012.11"},{"issue":"1","key":"3167_CR28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12911-022-01883-w","volume":"31","author":"S Wang","year":"2022","unstructured":"Wang S, Lu Q, Ye Z, et al. Effects of a smartphone application named shared decision making assistant for informed patients with primary liver cancer in decision-making in China: a quasi-experimental study. BMC Med Inf Decis Mak. 2022;31(1):145. https:\/\/doi.org\/10.1186\/s12911-022-01883-w","journal-title":"BMC Med Inf Decis Mak May"},{"issue":"7","key":"3167_CR29","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S1470-2045(21)00151-0","volume":"22","author":"PR Galle","year":"2021","unstructured":"Galle PR, Finn RS, Qin S, et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(7):991\u20131001. https:\/\/doi.org\/10.1016\/S1470-2045(21)00151-0","journal-title":"Lancet Oncol Jul"},{"issue":"3","key":"3167_CR30","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1200\/JCO.2015.62.0468","volume":"20","author":"KR Yabroff","year":"2016","unstructured":"Yabroff KR, Dowling EC, Guy GP Jr., et al. Financial hardship associated with cancer in the United States: findings from a population-based sample of adult cancer survivors. J Clin Oncol. 2016;20(3):259\u201367. https:\/\/doi.org\/10.1200\/JCO.2015.62.0468","journal-title":"J Clin Oncol Jan"},{"issue":"2","key":"3167_CR31","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1200\/JOP.2014.001542","volume":"11","author":"SY Zafar","year":"2015","unstructured":"Zafar SY, McNeil RB, Thomas CM, Lathan CS, Ayanian JZ, Provenzale D. Population-based assessment of cancer survivors\u2019 financial burden and quality of life: a prospective cohort study. J Oncol Pract. 2015;11(2):145\u201350. https:\/\/doi.org\/10.1200\/JOP.2014.001542","journal-title":"J Oncol Pract Mar"},{"issue":"5","key":"3167_CR32","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1200\/JOP.2013.001322","volume":"10","author":"KM Fenn","year":"2014","unstructured":"Fenn KM, Evans SB, McCorkle R, et al. Impact of financial burden of cancer on survivors\u2019 quality of life. J Oncol Pract. 2014;10(5):332\u20138. https:\/\/doi.org\/10.1200\/JOP.2013.001322","journal-title":"J Oncol Pract Sep"},{"issue":"2","key":"3167_CR33","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jval.2022.12.004","volume":"26","author":"JFP Bridges","year":"2023","unstructured":"Bridges JFP, de Bekker-Grob EW, Hauber B, et al. A roadmap for increasing the usefulness and impact of patient-preference studies in decision making in health: a good practices report of an ISPOR task force. Value Health. 2023;26(2):153\u201362. https:\/\/doi.org\/10.1016\/j.jval.2022.12.004","journal-title":"Value Health Feb"},{"issue":"3","key":"3167_CR34","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681\u201393. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018","journal-title":"J Hepatol Mar"},{"issue":"3","key":"3167_CR35","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1089\/jpm.2022.0338","volume":"26","author":"M Verma","year":"2023","unstructured":"Verma M, Kalman R, Horrow J, Gallagher M, Woodrell C, Navarro V. Feasibility of a palliative care intervention within routine care of hepatocellular carcinoma: a pilot randomized controlled trial. J Palliat Med. 2023;26(3):334\u201341. https:\/\/doi.org\/10.1089\/jpm.2022.0338","journal-title":"J Palliat Med Mar"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03167-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-024-03167-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03167-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T12:04:38Z","timestamp":1709121878000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03167-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3167"],"URL":"https:\/\/doi.org\/10.1186\/s12876-024-03167-1","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]},"assertion":[{"value":"26 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AMM: Consultant for TARGET RWE. ASB: Consultant for TARGET RWE. DME: Consultant for HighTide Therapeutics USA. For other authors, there are no additional disclosures or potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}